Teva Pharmaceuticals
TEVA
540 hedge funds and large institutions have $11.9B invested in Teva Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 54 funds opening new positions, 203 increasing their positions, 163 reducing their positions, and 70 closing their positions.
89% more call options, than puts
Call options by funds: $589M | Put options by funds: $312M
25% more repeat investments, than reductions
Existing positions increased: 203 | Existing positions reduced: 163
9% more capital invested
Capital invested by funds: $11B → $11.9B (+$977M)
0.17% less ownership
Funds ownership: 62.33% → 62.16% (-0.17%)
4% less funds holding
Funds holding: 562 → 540 (-22)
12% less funds holding in top 10
Funds holding in top 10: 26 → 23 (-3)
23% less first-time investments, than exits
New positions opened: 54 | Existing positions closed: 70
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HIIFS
Harel Insurance Investments & Financial Services
Ramat Gan,
Israel
|
+$183M |
| 2 |
PF
Phoenix Financial
Givatayim,
Israel
|
+$166M |
| 3 |
MMH
Menora Mivtachim Holdings
Ramat Gan,
Israel
|
+$150M |
| 4 |
PC
PointState Capital
New York
|
+$90.1M |
| 5 |
MC
Maverick Capital
Dallas,
Texas
|
+$70.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$397M |
| 2 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
-$87.6M |
| 3 |
Millennium Management
New York
|
-$70.9M |
| 4 |
Morgan Stanley
New York
|
-$70.7M |
| 5 |
Citigroup
New York
|
-$47.7M |
TEVA Hedge Fund Activity: Q2 2025 in Review
540 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q2 2025, worth a combined $11.9B — up 8.9% from $11B a quarter earlier.
Sellers outnumbered buyers: 70 funds closed out of TEVA and 54 opened new positions — a net loss of 16 holders — while 163 trimmed existing stakes and 203 added.
The largest buyer was Harel Insurance Investments & Financial Services, adding an estimated $183M. The largest seller was Fidelity Investments, cutting an estimated $397M.
- 540 institutional investors held Teva Pharmaceuticals (TEVA) as of Q2 2025, down from 562 in Q1 2025.
- Funds reported $11.9B of Teva Pharmaceuticals stock for Q2 2025, up 8.9% quarter-over-quarter.
- 54 funds opened new Teva Pharmaceuticals positions in Q2 2025 and 70 closed out, a net change of -16 holders.
- The largest Teva Pharmaceuticals buyer in Q2 2025 was Harel Insurance Investments & Financial Services, an estimated $183M added.
- The largest Teva Pharmaceuticals seller in Q2 2025 was Fidelity Investments, an estimated $397M sold.
Based on aggregated 13F filings for Q2 2025.